These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 3518529)

  • 1. Immunotherapy with yellow jacket venom. A comparative study including three different extracts, one adsorbed to aluminium hydroxide and two unmodified.
    Mosbech H; Malling HJ; Biering I; Böwadt H; Søborg M; Weeke B; Løwenstein H
    Allergy; 1986 Feb; 41(2):95-103. PubMed ID: 3518529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy with aluminum hydroxide adsorbed insect venom extracts (Alutard SQ): immunologic and clinical results of a prospective study over 3 years.
    Wyss M; Scheitlin T; Stadler BM; Wüthrich B
    Allergy; 1993 Feb; 48(2):81-6. PubMed ID: 8457037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IgE, IgG, IgG1 and IgG4 patterns in yellow jacket allergic patients during immunotherapy with a venom depot extract.
    Jeep S; Meysel U; Kunkel G
    Clin Exp Allergy; 1992 Feb; 22(2):297-302. PubMed ID: 1571821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the allergenicity and antigenicity of yellow jacket and hornet venoms.
    Reisman RE; Mueller U; Wypych J; Elliott W; Arbesman CE
    J Allergy Clin Immunol; 1982 Mar; 69(3):268-74. PubMed ID: 6801104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of an in-hospital insect sting challenge as a criterion for application or omission of venom immunotherapy.
    Blaauw PJ; Smithuis OL; Elbers AR
    J Allergy Clin Immunol; 1996 Jul; 98(1):39-47. PubMed ID: 8765816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety.
    Müller U; Helbling A; Berchtold E
    J Allergy Clin Immunol; 1992 Feb; 89(2):529-35. PubMed ID: 1740583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring of antibodies in patients on immunotherapy with insect venoms by immunoblotting.
    Einarsson R
    Int Arch Allergy Appl Immunol; 1987; 83(2):217-9. PubMed ID: 3294603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The VISYT trial: Venom Immunotherapy Safety and Tolerability with purified vs nonpurified extracts.
    Bilò MB; Severino M; Cilia M; Pio A; Casino G; Ferrarini E; Campodonico P; Milani M
    Ann Allergy Asthma Immunol; 2009 Jul; 103(1):57-61. PubMed ID: 19663128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse reactions to venom immunotherapy.
    Ramirez DA; Londono S; Evans R
    Ann Allergy; 1981 Dec; 47(6):435-9. PubMed ID: 7325415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evaluation of the common diagnostic methods of hypersensitivity for bee and yellow jacket venom by means of an in-hospital insect sting.
    Blaauw PJ; Smithuis LO
    J Allergy Clin Immunol; 1985 May; 75(5):556-62. PubMed ID: 3989140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of prolonged venom immunotherapy in children.
    Graft DF; Schuberth KC; Kagey-Sobotka A; Kwiterovich KA; Niv Y; Lichtenstein LM; Valentine MD
    J Allergy Clin Immunol; 1987 Aug; 80(2):162-9. PubMed ID: 3611537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies of coexisting honeybee and vespid-venom sensitivity.
    Reisman RE; Müller UR; Wypych JI; Lazell MI
    J Allergy Clin Immunol; 1984 Feb; 73(2):246-52. PubMed ID: 6699307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rush hymenoptera venom immunotherapy is efficacious and safe.
    Pasaoglu G; Sin BA; Misirligil Z
    J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious.
    Goldberg A; Confino-Cohen R
    J Allergy Clin Immunol; 2001 May; 107(5):902-6. PubMed ID: 11344360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rush Hymenoptera venom immunotherapy: a safe and practical protocol for high-risk patients.
    Sturm G; Kränke B; Rudolph C; Aberer W
    J Allergy Clin Immunol; 2002 Dec; 110(6):928-33. PubMed ID: 12464961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The IgE and IgG subclass antibody response in patients allergic to yellow jacket venom undergoing different regimens of venom immunotherapy.
    Djurup R; Malling HJ; Søndergaard I; Weeke B
    J Allergy Clin Immunol; 1985 Jul; 76(1):46-55. PubMed ID: 4008813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IgG and IgE antibodies after immunotherapy with bee and wasp venom.
    Kemeny DM; Lessof MH; Patel S; Youlten LJ; Williams A; Lambourn E
    Int Arch Allergy Appl Immunol; 1989; 88(1-2):247-9. PubMed ID: 2707888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A controlled trial of immunotherapy in insect hypersensitivity.
    Hunt KJ; Valentine MD; Sobotka AK; Benton AW; Amodio FJ; Lichtenstein LM
    N Engl J Med; 1978 Jul; 299(4):157-61. PubMed ID: 78446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical correlation of the venom-specific IgG antibody level during maintenance venom immunotherapy.
    Golden DB; Lawrence ID; Hamilton RH; Kagey-Sobotka A; Valentine MD; Lichtenstein LM
    J Allergy Clin Immunol; 1992 Sep; 90(3 Pt 1):386-93. PubMed ID: 1527321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical relevance of the venom-specific immunoglobulin G antibody level during immunotherapy.
    Golden DB; Meyers DA; Kagey-Sobotka A; Valentine MD; Lichtenstein LM
    J Allergy Clin Immunol; 1982 Jun; 69(6):489-93. PubMed ID: 7076990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.